Generate Biomedicines, Inc. priced its initial public offering at $16.00 per share, selling 25 million shares of common stock and aiming to generate $400.0 million in gross proceeds before accounting for underwriting discounts and commissions.
The company has given the underwriting syndicate a 30-day option to acquire up to an additional 3.75 million shares at the IPO price, subject to the customary deductions for underwriting discounts and commissions. All shares included in the offering are being sold by Generate Biomedicines.
Generate's common stock is scheduled to begin trading on the Nasdaq Global Select Market on February 27, 2026, under the ticker symbol "GENB." The offering is expected to close on March 2, 2026, contingent on customary closing conditions.
Goldman Sachs & Co. LLC and Morgan Stanley are acting as joint lead book-running managers for the transaction. Piper Sandler, Guggenheim Securities, and Cantor are serving as book-running managers.
Headquartered in Somerville, Massachusetts, Generate Biomedicines describes itself as a clinical-stage company applying artificial intelligence to biotechnology, with a focus on drug design and development.
Regulatory clearance for the offering moved forward when the U.S. Securities and Exchange Commission declared the company's registration statement effective on February 26, 2026. The offering is being conducted solely through a prospectus, and copies are available from the underwriters upon request.
Investors considering the deal should note that the stated $400.0 million figure is a gross amount that does not reflect the impact of underwriting discounts and commissions, and the final size of the issuance may change if the underwriters exercise their option to purchase additional shares.
Offer specifics and timeline
- Price per share: $16.00
- Primary shares offered: 25,000,000
- Overallotment option: up to 3,750,000 additional shares (30 days)
- Expected Nasdaq listing date: February 27, 2026 (ticker: GENB)
- Anticipated closing date: March 2, 2026, subject to customary closing conditions
Company description
Generate Biomedicines identifies itself as a clinical-stage generative biology company that leverages artificial intelligence for biotechnology applications, including drug design and development. The company is based in Somerville, Massachusetts.
Regulatory and offering mechanics
The SEC declared the registration statement effective on February 26, 2026, clearing a regulatory step necessary for the offering. The offering is being made only via a prospectus, and interested parties may request copies from the underwriters.